In this presentation, the speakers will report the results of a series of three population-based cohort studies relating to the use and effects of smoking cessation pharmacotherapies. The first of these studies provides evidence on how the three smoking cessation pharmacotherapies available in Australia (nicotine replacement therapy, varenicline and bupropion) compare to each other in terms of cardiovascular safety. 

The second study measures the prevalence of use of these pharmacotherapies among patients who were hospitalised in NSW for a major cardiovascular disease. Our third study, also based on patients who were hospitalised for a major cardiovascular disease, compares the effectiveness of nicotine replacement therapy and varenicline in preventing recurrent cardiovascular events.